MoneyWorks4Me

Gland Pharma - Quaterly Results

11 Aug 2026 Evaluate
A fair growth of 23.85% in the revenue at Rs. 12866.40 millions was reported in the June 2026 quarter as compared to Rs. 10388.35 millions during year-ago period.Good  Net Profit growth of 35.33% reported above the corresponding previous quarter figure of Rs. 2692.58 millions to Rs. 3643.91 millioins.Operating profit for the quarter ended June 2026 rose to 5323.34 millions as compared to 4135.86 millions of corresponding quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 12866.40 10388.35 23.85 12866.40 10388.35 23.85 45520.92 41161.49 10.59
Other Income 588.21 547.41 7.45 588.21 547.41 7.45 3038.97 2150.75 41.30
PBIDT 5323.34 4135.86 28.71 5323.34 4135.86 28.71 19669.73 16576.93 18.66
Interest 6.91 74.35 -90.71 6.91 74.35 -90.71 180.73 228.37 -20.86
PBDT 5316.43 4061.51 30.90 5316.43 4061.51 30.90 19245.54 16348.56 17.72
Depreciation 439.53 437.68 0.42 439.53 437.68 0.42 1762.43 1692.71 4.12
PBT 4876.90 3623.83 34.58 4876.90 3623.83 34.58 17483.11 14655.85 19.29
TAX 1232.99 931.25 32.40 1232.99 931.25 32.40 4487.60 3758.32 19.40
Deferred Tax -18.93 -1.46 1196.58 -18.93 -1.46 1196.58 -38.29 91.24 -141.97
PAT 3643.91 2692.58 35.33 3643.91 2692.58 35.33 12995.51 10897.53 19.25
Equity 164.96 164.76 0.12 164.96 164.76 0.12 164.76 164.76 0.00
PBIDTM(%) 41.37 39.81 3.92 41.37 39.81 3.92 43.21 40.27 7.29

Gland Pharma Share Price

2871.50 208.00 (7.81%)
11-Aug-2026 12:15 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1931.85
Dr. Reddys Labs. 1197.45
Cipla 1462.10
Lupin 2262.40
Zydus Lifesciences 1151.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: